The Journal of Alzheimer’s Disease has published the paper: Effect size analyses of Souvenaid®, in patients with Alzheimer’s disease, showing a favourable risk ratio for Souvenaid use in clinical practice.
The objective of the study was to determine effect sizes observed in clinical trials of Souvenaid, a medical nutrition drink. An effect size study is a statistical method that allows researchers to standardize results of different clinical studies, making it is possible to calculate the number of patients needed to show benefit.
Souvenaid was developed to support the nutritional needs of early Alzheimer’s patients. The paper clearly shows that there is no safety risks associated with using Souvenaid and that Souvenaid can achieve clinically detectable effects in patients with early Alzheimer. The research was conducted by many highly respected authors in the Alzheimer’s field. It was the first time the effect sizes of the various clinical trials were presented together.
John Sijben, R&D Director Adult Therapeutic Areas & Clinical Trials at Danone Research & Innovation: “We’re very pleased with both the initiative and of course the outcome of the research. The paper provides a relevant contribution to all experts in the Alzheimer’s field. It is an important step in building clinical evidence in patients with early Alzheimer’s.”